AllSci News
Imvax achieves survival boost in glioblastoma with IGV-001
Imvax, a biotech based in Philadelphia, announced top-line results from a randomized, multicenter Phase 2b trial for IGV-001 in patients with newly…
Janux posts Phase 1 data for PSMA-directed TCE in mCRPC
San Diego-based biotech Janux Therapeutics released updated interim data from its Phase 1 clinical trial of JANX007, a first-in-class, PSMA-targeted T-cell engager…
Generate:Biomedicines advances AI-engineered asthma antibody into global Phase 3 trials with twice-yearly dosing
Generate:Biomedicines announced plans to launch two global Phase 3 clinical trials, SOLAIRIA-1 and SOLAIRIA-2, to evaluate GB-0895, a long-acting anti-TSLP monoclonal antibody…
IDEAYA’s first-in-class B7H3/PTK7 ADC to enter the clinic following FDA IND
US biotech IDEAYA Biosciences has secured US FDA clearance for an Investigational New Drug (IND) application for IDE034, a potential global first-in-class…
Innovent secures China approval for first domestic IL-23p19 antibody picankibart
China’s National Medical Products Administration (NMPA) issued a first market approval to Innovent Biologics’ Pecondle (picankibart), the country’s first domestically developed IL-23p19…
Novo Nordisk’s amycretin demonstrates best-in-class potential in Phase 2
Novo Nordisk is gaining confidence in its dual GLP-1/amylin agonist pipeline candidate amycretin after the molecule delivered substantial improvements in both glycemic…
Mabwell launches Phase I/II trials for CDH17 ADC
China-based biotech Mabwell is initiating two Phase I/II clinical trials of its CDH17-targeted antibody–drug conjugate (ADC) 7MW4911. The China study (CTR20254163) will…
Mazdutide delivers up to 20% weight loss in Innovent’s Phase 3 trial
Innovent Biologics reported that mazdutide 9 mg, a potential first-in-class dual GCG/GLP-1 receptor agonist, achieved up to 20.1% weight loss in Chinese…
Novo’s Alzheimer’s Hail Mary for semaglutide fails in EVOKE Phase 3 trials
Novo Nordisk A/S disclosed that its bid to expand the repertoire of GLP-1 receptor agonist semaglutide to Alzheimer’s disease (AD) has failed.…
MSD and Kelun’s TROP2 ADC succeeds in Keytruda combo for NSCLC
Merck & Co. partner Sichuan Kelun Biotech Biopharmaceutical announced another Phase 3 success for the TROP2-targeted antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT;…
J&J halts study for tau-targeted Alzheimer’s antibody
Johnson & Johnson (J&J) has discontinued the Phase 2b AuTonomy trial evaluating its tau-targeted monoclonal antibody posdinemab (JNJ-63733657) in early Alzheimer’s disease…
PeproMene showcases breakthrough BAFF-R CAR-T results in CD19-escape B-cell malignancies at ASH 2025
US-based cell therapy developer PeproMene Bio announced that its BAFF‑R‑targeted autologous CAR T candidate, PMB‑CT01, has been selected for two oral presentations at…
Unlocking the Secrets Behind Top Drugs
“The difference between good pharmaceutical investing and great pharmaceutical investing isn’t access to data—it’s the ability to decode the science behind the…
How AERIS AI is Revolutionizing Scientific Research
“The future of research isn’t about reading more papers—it’s about understanding them better, faster, and with complete transparency.” How AERIS AI is…
AllSci Wins Grant to Expand AI Platform
Empowering researchers at every level to test hypotheses, validate findings, and collaborate to advance science AllSci Wins Grant to Expand AI Platform…
The AllSci Brief
Free, systematic R&D and deal news. Daily.